Piper Sandler Increases ImmunityBio (NASDAQ:IBRX) Price Target to $5.00

ImmunityBio (NASDAQ:IBRX) had its price objective boosted by Piper Sandler from $4.00 to $5.00 in a report published on Monday, Benzinga reports. The firm currently has a neutral rating on the stock.

ImmunityBio Price Performance

NASDAQ IBRX opened at $5.37 on Monday. The firm has a market cap of $3.62 billion, a PE ratio of -4.63 and a beta of 1.24. ImmunityBio has a one year low of $1.25 and a one year high of $6.93. The stock’s 50 day simple moving average is $4.60 and its 200 day simple moving average is $3.62.

Institutional Investors Weigh In On ImmunityBio

A number of large investors have recently bought and sold shares of IBRX. Apollon Wealth Management LLC bought a new stake in ImmunityBio during the 1st quarter worth approximately $25,000. Traynor Capital Management Inc. bought a new position in ImmunityBio in the 3rd quarter valued at $25,000. Aire Advisors LLC bought a new position in ImmunityBio in the 3rd quarter valued at $25,000. FMR LLC boosted its position in ImmunityBio by 190.0% in the 3rd quarter. FMR LLC now owns 14,881 shares of the company’s stock valued at $25,000 after buying an additional 9,749 shares during the last quarter. Finally, WINTON GROUP Ltd bought a new position in ImmunityBio in the 3rd quarter valued at $26,000. 8.58% of the stock is currently owned by institutional investors.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies.